Summary Using two monoclonal antibodies directed against placental alkaline phosphatase (H17E2 and D20L) the immunohistological staining of testicular germ cell tumours was compared with that of a wide range of normal and malignant tissues. All seminomas and malignant teratomas tested gave strong positive labelling with H17E2 but were either negative or only patchily positive with D20L. Neither antibody gave any positive reaction on the normal tissues tested. All other malignancies were negative with both antibodies apart from two cases of ovarian and one case of endometrical cancer (strongly stained by H17E2) and three cases of colonic carcinoma (weakly and patchily stained by both H17E2 and D20L). This indicates that germ cell neoplasms generally express a form of placental alkaline phosphatase recognised by antibody H17E2.
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It has long been recognised that the placenta produces a form of alkaline phosphatase which can be distinguished from the intestinal and liver isozymes immunologically and by its heat stability and susceptibility to various noncompetitive inhibitors. Placental alkaline phosphatase is a cell surface glycoprotein consisting of two subunits both of approximately 67,000 daltons in molecular weight (Budger & Sussman, 1976) . It is known to be highly polymorphic with more allelic forms than any other human enzyme studied (Harris, 1982) . The ectopic appearance of placental alkaline phosphatase has been reported using polyclonal antisera in a wide range of neoplasms including testis, ovary, lung, stomach and pancreas (Fishman et al., 1976 (Fishman et al., , 1968 Stolbach et al., 1969; Nathanson & Fishman, 1971) . It has also been reported to be present in small amounts in normal cervix, lung and a placental like form in the testis (Goldstein et al., 1982; Chang et al., 1980 (Kohler & Milstein, 1975) against the colon carcinoma cell line LoVo (Stragaard et al., 1980) phosphatase (Travers & Bodmer, in preparation) . H17E2 also reacts with the leucine inhibitable form of alkaline phosphatase found at low levels in the normal testis and which is immunologically cross reactive with the placental enzyme (Harris, 1982) . It did not cross react with other non-placental forms of alkaline phosphatase.
(c) 11-4.1. This antibody is directed against the mouse H-2Kk antigen (equivalent to human HLA) and does not cross react with any human tissues (Oi et al., 1979) . This was used as a negative control.
Immunoperoxidase reaction The cryostat sections were incubated with one of the monoclonal anti-placental alkaline phosphatase antibodies (as neat tissue culture supernatant (10 pg ml -1) followed by peroxidase conjugated rabbit anti-mouse immunoglobulin (Dako Immunoglobulins a/s). The peroxidase reaction was developed using diaminobenzidine and hydrogen peroxide. Sections were then counterstained with haematoxylin and mounted for microscopical examination.
Results
Normal tissues Both monoclonal anti-placental alkaline phosphatase antibodies gave strong immunohistochemical reactions with human placental syncytiotrophoblast (Figure 1 ). A range of normal human tissues was tested using the same immunoperoxidase techniques (Table I ) but neither Figure 4 ) and thus contrasted with the reactivity of testicular tumours.
Malignant tumours
A wide range of biopsies from malignant tumours (Table II) was examined with both antibodies. Sixteen testicular tumours including seminomas and malignant teratomas (detailed in Table II ) all gave positive reactions with H17E2 (Figures 2 and 3 ).
D20L showed a more restricted staining pattern labelling only a small minority of cells in three cases of seminoma. All the other tumours examined (Table II) were negative with both antibodies apart from one case of papillary serous adenocarcinoma of the ovary, a secondary poorly differentiated carcinoma of the ovary and a poorly differentiated carcinoma of the uterus (all strongly positive with H17E2) and three cases of colonic carcinoma (weakly and patchily stained with both antibodies).
Negative control antibody 11-4.1 produced a negative reaction against all tested tissues.
Discussion
This study has identified a monoclonal antibody H17E2 that reacts strongly with germ cell tumours of the testis and some carcinomas of the female genital tract. No normal tissues showed any reactivity apart from placental syncytiotrophoblast against which the antibody was raised.
Previous studies using polyclonal antisera have provided evidence for the presence of placental alkaline phosphatase in a wide range of human neoplasms, e.g. seminoma of testis and tumours of breast, ovary, lung, stomach and pancreas (Fishman et al., 1968; Stolbach et al., 1979; Nathanson & Fishman, 1971; Uchida et al., 1981; Wada et al., 1979) as well as in some normal tissues such as cervix, lung and testes (Goldstein et al., 1982; Chang et al., 1980) . It is known that placental alkaline phosphatase is a highly complex enzyme (Harris, 1982) which has been demonstrated in this study by the different patterns of staining of the two separate monoclonal antibodies directed against placental alkaline phosphatase. This study indicates that there is a particular epitope carried by the enzyme which is present in high concentration on normal human placental syncytiotrophoblast, testicular germ cell tumours and some tumours of the female genital tract. In addition it would appear that the antigenic forms recognised by both antibodies are present focally and at much lower concentrations in some (Travers & Bodmer, in preparation) . It is interesting that antibody D20L showed a narrower distribution reacting only with some seminomas. It seems likely therefore, that the alkaline phosphatase found in germ cell tumours is the testis specific form of the enzyme rather than the placental form. This enzyme is expressed at low levels in the normal testis (Harris, 1982) presumably below the threshold of detectability by this study, but appears in these tumours at elevated levels. In the colon and uterine tumours, since D20L also shows reactivity, it is likely that there is a true ectopic expression of the placental isozyme.
For clinical use antibody H 1 7E2 might be a useful adjunct in the histopathological diagnosis of testicular germ cell tumours providing that the patchy weak reactivity with several of the cases of colonic carcinoma is borne in mind. It could also be incorporated in a radioimmunoassay (RIA) or an enzyme linked immunoabsorbent assay (ELISA) for monitoring the status of patients with germ cell tumours as previously described by others using both polyclonal antisera and monoclonal antibodies (Lange, 1982; Millan et al., 1982; McLaughlin et al., 1982) .
However, the potential importance of H17E2 is that in view of its specificity for placental alkaline phosphatase and the apparent absence of reactivity with normal tissues other than placenta, it could be used in vivo for tumour localisation studies. Previous studies from this and other centres (Epenetos et al., 1982; Farrands et al., 1982; Berche et al., 1982) using other tumour-associated monoclonal antibodies have shown promising results with this approach as a means of localising accurately the site and extent of tumours in individual patients. Furthermore, its apparent lack of reactivity with normal tissues renders it potentially useful as a therapeutic agent in the treatment of testicular germ cell tumours.
